Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2423-2429

  Yamaguchi, Tomohiro ^a,c   Bamba, Kenzo ^a,b   Kitayama, Ayari ^a   Kuroiwa, Yasuyuki ^a   Yoshimatsu, Kazuhiko ^b   Shimakawa, Takeshi ^b   Ogawa, Kenji ^b   Sekine, Teruaki ^a,b,c   Shimizu, Norio ^c   Yamamoto, Kohtaro ^c  

^a Lymphotec Inc   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Antinuclear antibody; Autoimmune disease; Autologous activated lymphocyte; Rheumatoid factor

Indexed keywords

ANTINUCLEAR ANTIBODY; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; OKT 3; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; AUTOLOGOUS ACTIVATED LYMPHOCYTE; CANCER THERAPY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER CARCINOMA; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; OVARY CANCER; PRIORITY JOURNAL; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD3; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASMS; RHEUMATOID FACTOR;

EID: 4444222734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rosenberg SA, Lotze MT, Mull LM, Chang AE, Avis FP, Leitman S, Lineman WM, Pobertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 316: 889-897, 1987.
2. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K and Kakizoe T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy. Biomed Pharmacother 47: 73-78, 1993.
3. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356: 802-807, 2000.
4. Takeda S, Takagi A, Kinoshita K, Sugawara I, Watanabe M, Itoyama S, Suzuki H, Kimura M and Sekine T: Clinical effect of adoptive immunotherapy with immobilized anti-CD3 antibody-activated T lymphocytes for advanced ovarian cancer. J Jap Soci Cancer Ther 30: 63-67, 1995.
5. Shibui S, Tanaka M, Nomura K and Sekine T: Treatment of malignant brain tumors using immobilized anti-CD3 antibody-activated T lymphocytes. BCG•BRM Ryouhoushi 23: 39-45, 1999 (in Japanese with English abstract).
6. Ishiyama K, Saigusa M, Nishii O, Ikeda M, Kido M, Koizumi Y, Takeuchi T, Kojima T, Kato Y, Kawana T, Takizawa K, Suzuki S and Sekine T: Adoptive immunotherapy, effective in a recurrent case of malignant melanoma of vagina. J Obst Gyn Res (Tokyo) 48: 146-149, 1999.
7. Kawamura A, Sekine T, Sekiguchi M, Yanoma S, Kaneko A, Haneda T, Moriya Y, Hayasaka K and Kakizoe T: Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy. Jpn J Clin Oncol 30: 267-271, 2000.
8. Azuma H, Oshima M, Ito K, Okuno A, Kawabata I, Banba K, Murahashi H, Sekine T, Kato Y, Ikebuchi K and Ikeda H: Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 159: 633-634, 2000.
9. Morio T: The molecular basis of primary immunodeficiency syndrome and the current therapeutic approach for the disease. Rinsho Byori 47: 519-524, 1999 (in Japanese with English abstract).
10. Shimizu N, Sekine T, Itoh K, Nakamura T, Iwamoto A, Satoh Y and Yamamoto K: Large-scale ex vivo expansion of primary T lymphocyte in late-stage AIDS patients. AIDS Res Hum Retroviruses 16: 611-612, 1999.
11. Ebina T, Ogama N, Shimanuki H, Kubota T and Isono N: Effector mechanism and clinical response of BAK (BRM-Activated Killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (Neuro-Immune-Endocrine) cells. Microbiol Immunol 45: 403-411, 2001.
12. Chen FX, Liu JQ, Zhang NZ, Gong XJ, Zhang GL, Xu YM, Zhou ZH, Wang T and Huang J: Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor. Ai Zheng 21: 797-801, 2002.
13. Sekine T: Expansion of peripheral blood lymphocyte by culture with immobilized anti-CD3 antibody and IL-2. Human Cell 5: 243-246, 1992.
14. Yamaguchi T, Fujimiya Y, Suzuki Y, Katakura R and Ebina T: A simple method for the propagation and purification of γδ T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J Immunol Methods 205: 19-28, 1997.
15. Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T and Ebina T: In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) γδ T cells from glioblastoma patients. Clin Cancer Res 3: 633-643, 1997.
16. Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J and Fujimiya Y: Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood γδ T cells isolated from glioblastoma patients. Cancer Immunol Immunother 47: 97-103, 1998.
17. Ernerudh J, Berlin G and Ekerfelt C: The use of cell products for treatment of autoimmune neuroinflammatory disease. Curr Med Chem 9: 1497-1505, 2002.